EGFR and neoplasm: One study expresses anti-CD3 and anti-tumor cell associated epidermal growth factor receptor (EGFR) molecules on the surface of exosomes by genetic engineering, thereby generating a drug (aCD3-a EGFR SMART-Exos) that simultaneously targets T cells (CD3) and tumor cells (EGFR), activating cytotoxic T cells to attack tumor cells expressing EGFR.